Laura Holman to Humans
This is a "connection" page, showing publications Laura Holman has written about Humans.
Connection Strength
0.576
-
Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study. Nutr Cancer. 2023; 75(2):662-669.
Score: 0.047
-
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecol Oncol. 2020 01; 156(1):100-106.
Score: 0.038
-
Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough. Gynecol Oncol. 2018 04; 149(1):89-92.
Score: 0.034
-
An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers. Clin Ther. 2018 03; 40(3):372-388.
Score: 0.034
-
Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33.
Score: 0.032
-
Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report. BMC Cancer. 2015 Oct 17; 15:728.
Score: 0.029
-
Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014 May; 133(2):283-6.
Score: 0.026
-
Sentinel lymph node evaluation in women with cervical cancer. J Minim Invasive Gynecol. 2014 Jul-Aug; 21(4):540-5.
Score: 0.025
-
Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6.
Score: 0.025
-
Genetic risk and gynecologic cancers. Hematol Oncol Clin North Am. 2012 Feb; 26(1):13-29.
Score: 0.022
-
Discussion: 'Treatment of symptomatic uterine fibroids' by van der Kooij et al. Am J Obstet Gynecol. 2010 Aug; 203(2):e1-6.
Score: 0.020
-
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. Gynecol Oncol. 2025 Apr; 195:122-133.
Score: 0.014
-
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278). Gynecol Oncol. 2025 Apr; 195:50-58.
Score: 0.014
-
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278). Gynecol Oncol. 2025 Apr; 195:59-65.
Score: 0.014
-
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2025 Feb 15; 131(4):e35757.
Score: 0.014
-
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. Nat Commun. 2025 Jan 09; 16(1):553.
Score: 0.014
-
Symptom trajectories over time by cannabis use status among patients undergoing cancer treatment. Sci Rep. 2024 11 16; 14(1):28319.
Score: 0.013
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992.
Score: 0.013
-
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70?years and over. Gynecol Oncol. 2024 08; 187:221-226.
Score: 0.013
-
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10; 42(20):2425-2435.
Score: 0.013
-
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
Score: 0.011
-
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
Score: 0.011
-
Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecol Oncol. 2021 09; 162(3):532-538.
Score: 0.011
-
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 05 15; 27(10):2734-2741.
Score: 0.010
-
Pathologic and clinical tumor size discordance in early-stage cervical cancer: Does it matter? Gynecol Oncol. 2020 11; 159(2):354-358.
Score: 0.010
-
Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. J Clin Oncol. 2020 04 01; 38(10):1030-1040.
Score: 0.010
-
Multiple Luteinized Follicle Cysts of the Ovary in a Patient With a Pituitary Adenoma: Report of a Case and Review of the Literature. Int J Gynecol Pathol. 2019 Nov; 38(6):562-567.
Score: 0.009
-
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. Gynecol Oncol. 2019 09; 154(3):461-466.
Score: 0.009
-
Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecol Oncol. 2018 07; 150(1):79-84.
Score: 0.009
-
Adenocarcinoma of the cervix involving the fallopian tube mucosa: report of a case. Diagn Pathol. 2016 Aug 17; 11(1):77.
Score: 0.008
-
Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016 08; 142(2):225-30.
Score: 0.007
-
Laparoscopic supracervical hysterectomy with morcellation: should it stay or should it go? J Minim Invasive Gynecol. 2015 Feb; 22(2):185-92.
Score: 0.007
-
Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study. Gynecol Oncol. 2014 Aug; 134(2):379-84.
Score: 0.007
-
Update on sentinel lymph node evaluation in gynecologic malignancies. Curr Opin Obstet Gynecol. 2011 Feb; 23(1):8-12.
Score: 0.005